在长期护理机构居住的老年人中优化过度活跃的膀药物
1Clinical Pharmacist, LECOM Health, Erie, Pennsylvania.
The Senior care pharmacist
|March 26, 2025
概括
药剂师可以优化长期护理中老年人的过度活性膀 (OAB) 药物. 这种干预减少了抗胆固醇副作用,但没有加剧OAB症状,改善了患者的生活质量.
科学领域:
- 老年病的医生 老年病的医生
- 药理学 药理学是指药理学的学科.
- 提高质量 提高质量
背景情况:
- 尿失禁,特别是膀过活 (OAB),显著影响老年人的健康和生活质量.
- 通常用于OAB的抗胆固醇药物对老年人有明显的副作用,需要谨慎管理.
- 药剂师在优化长期护理环境中的OAB药物治疗方案方面处于良好地位.
研究的目的:
- 减少在长期护理机构居住的老年人中不适当使用OAB药物.
- 评估药剂师主导的药物优化对抗胆固醇副作用和OAB症状控制的影响.
主要方法:
- 一个质量改善项目,涉及27名长期护理居民.
- 临床药剂师进行了药物审查和患者采访,以评估OAB药物的适当性.
- 向医疗团队提供了治疗修改的建议,以减轻不良影响.
主要成果:
- 与非干预组 (10%) 相比,干预组中观察到抗胆固醇副作用的显著减少 (57.1%).
- 大多数患者没有经历OAB症状的恶化,尽管影响是可变的.
- 总共有14种OAB药物被处方停止或剂量减少.
结论:
- 在长期护理中的老年人中,药剂师主导的OAB药物的优化可以导致停止不必要的药物.
- 这种干预措施显示了改善不良影响概况的潜力,而不会影响OAB症状管理.
- 药剂师优化OAB药物治疗可以提高长期护理机构的患者护理和安全性.
相关概念视频
Drug Therapy
32
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
32
Drugs for Treatment of Diarrhea-Predominant IBS
131
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
131
Cholinergic Antagonists: Pharmacokinetics
391
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
391
Parkinson's Disease: Treatment
166
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
166
Factors Affecting Drug Response: Overview
1.8K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.8K
Alzheimer's Disease: Treatment
137
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
137


